
Tsukasa Hasegawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1622166/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. BMC Cancer, 2020, 20, 207.	1.1	26
2	Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 6851-6857.	0.5	24
3	Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. Lung Cancer, 2020, 144, 71-75.	0.9	21
4	Predictive factors for relapse of cryptogenic organizing pneumonia. BMC Pulmonary Medicine, 2019, 19, 10.	0.8	20
5	Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. In Vivo, 2020, 34, 2997-3003.	0.6	11
6	Poor efficacy of antiâ€programmed cell deathâ€1/ligand 1 monotherapy for nonâ€small cell lung cancer patients with active brain metastases. Thoracic Cancer, 2020, 11, 2465-2472.	0.8	7
7	Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. International Journal of Clinical Oncology, 2020, 25, 67-73.	1.0	6
8	Mild Lung Tuberculosis in a Patient Suffering from Status Epilepticus Caused by the Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH). Internal Medicine, 2017, 56, 429-433.	0.3	3
9	Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. Cancer Treatment and Research Communications, 2020, 25, 100249.	0.7	1
10	Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. International Journal of Clinical Oncology, 2021, 26, 507-514.	1.0	1